Bernard Lo and David L. DeMets
Sharing of data from clinical trials benefits patients by enabling new discoveries, meta-analyses, and confirmation of published results. As the table shows, the European Medicines Agency (EMA), a number of drug companies, and one other trial funder have already implemented data sharing. A comprehensive Institute of Medicine (IOM) report recommends the sorts of data that should be shared, how long after a trial, and under what conditions. The International Committee of Medical Journal Editors (ICMJE) proposes that the analytic data set supporting a published article be shared no later than 6 months after publication.